Details of the Drug Combination

General Information of Drug Combination (ID: DCA6O5U)

Drug Combination Name
LY2606368 LY-2228820
Indication
Disease Entry Status REF
Advanced Cancer Phase 1 [1]
Component Drugs LY2606368   DM4XMF7 LY-2228820   DMHXTNW
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of LY2606368
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [2]
Small-cell lung cancer 2C25.Y Phase 2 [2]
Head and neck cancer 2D42 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Squamous cell anal carcinoma 2C00.3 Phase 1 [4]
LY2606368 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Checkpoint kinase-1 (CHK1) TTTU902 CHK1_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of LY-2228820
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
LY-2228820 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Stress-activated protein kinase (p38) TTWELHI NOUNIPROTAC Inhibitor [5]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02860780) A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Eli Lilly.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).